What RFK Jr's Rogan interview actually said about peptide access vs. what the headlines claimed

Headlines moved fast. The regulatory process moves slowly. Here's what's actually in motion.

TL;DR

• RFK Jr made a podcast remark, not a formal HHS proposal — and a podcast appearance does not change federal law.
• The formal step came from FDA: on April 22, 2026, FDA removed 12 peptides from Category 2 after their nominations were withdrawn. They are not in Category 1 and are not on the 503A bulks list.
• FDA's advisory committee voted on seven of those peptides in July 2026. As of September 14, 2026, FDA has not made a final decision.

What it is

The Joe Rogan appearance sparked wide coverage because RFK Jr — as HHS Secretary — said on February 27, 2026 that FDA would act on peptides soon and that about 14 peptides would become more accessible. He said FDA had wrongly moved 19 peptides into "Category 2" in September 2023 (in plain English: FDA's list of substances that raise significant safety risks). It was an interview remark, not a formal HHS proposal, directive, rule, or press release. That's the actual story.

What actually happened

HHS did not publish a list or a Federal Register notice about the remark, and no source shows he named specific peptides. The formal actions that followed were FDA's. On April 15, 2026, FDA gave notice that 12 peptides would leave Category 2 because their nominations were withdrawn. On April 16, 2026, FDA published a Federal Register notice that scheduled a July 2026 advisory committee meeting. On April 22, 2026, FDA removed the 12 peptides from Category 2, including BPC-157 and thymosin beta-4 fragment (TB-500).

What the podcast coverage missed: an interview remark is not the same as an FDA action. Law firms also say removal from Category 2 does not, by itself, put a substance on the 503A bulks list or in Category 1. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon to the Section 503A bulk drug substances list, and voted against emideltide (DSIP). The committee is advisory. As of September 14, 2026, FDA has not made a final decision.

What it means for access right now

If you're asking whether BPC-157 or TB-500 is available from a 503A pharmacy today, the honest answer is: it depends on where you are and how carefully your pharmacy interprets the current enforcement environment. As of September 14, 2026, BPC-157 and TB-500 are not in any FDA 503A category and are not on the 503A bulks list. Some pharmacies have resumed compounding these peptides. Others are waiting for FDA's final decision.

The gray market — websites selling "research use only" peptides — is a different category entirely. That path bypasses the physician evaluation and pharmacy quality standards that make compounded peptides meaningful. See our piece on why Category 2 status and the gray market are not the same thing.

What the research context is

Advocacy for these peptides is based on decades of preclinical research — plus a growing body of physician experience. The 12 peptides removed from FDA restriction in 2026 post covers the specific compounds and the literature behind each.

The Halftime POV

Regulatory momentum matters, and FDA's 2026 list change is genuinely significant. But the distance between "removed from Category 2" and "final FDA decision" is exactly where patients get burned by acting too early. We'll update our protocols as each peptide formally clears the FDA process. Until then, we prescribe within the current framework — which is still quite substantial.

Related reading:

• 12 peptides removed from FDA restriction in 2026
• Category 1 vs. Category 2: what the distinction actually means
• Category 2 status vs. the gray market: why they're not the same

---

FAQ

Q: What did RFK Jr actually say about peptides on Joe Rogan? A: He said FDA would act on peptides soon and that about 14 peptides would become more accessible. He also said FDA had wrongly moved 19 peptides into Category 2 in September 2023. He did not announce that peptides were immediately legal, and the remark was not a formal HHS proposal.

Q: Did RFK Jr legalize peptides in 2026? A: No. He made an interview remark, not a formal proposal. The formal step was FDA's April 22, 2026 removal of 12 peptides from Category 2. As of September 14, 2026, those peptides are not in any FDA 503A category and are not on the 503A bulks list.

Q: Which peptides are affected? A: No source shows RFK Jr named specific peptides. FDA's April 22, 2026 change removed 12 peptides from Category 2, including BPC-157 and TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding BPC-157 and TB-500, among others, to the Section 503A bulk drug substances list. The committee is advisory. As of September 14, 2026, FDA has not made a final decision.

---

Disclaimer

This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary.

Get started

We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.

---

Sources

• HHS.gov — Compounding and the 503A Framework
• FDA.gov — Human Drug Compounding
• FDA Federal Register — Bulk Drug Substances Under Section 503A

---

This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.